FDA ad­comm to de­cide on mol­nupi­ravir EUA; Can­cer at­las un­veils new po­ten­tial drug tar­get

The FDA has an­oth­er ad­comm com­ing down the pipeline — this time on Covid-19 oral an­tivi­ral mol­nupi­ravir.

The fed­er­al agency’s ad­vi­so­ry com­mit­tee will meet on No­vem­ber 30th to go over Mer­ck and Ridge­back’s EUA re­quest for their in­ves­ti­ga­tion­al an­tivi­ral drug, and dis­cuss the avail­able da­ta sup­port­ing its use in Covid-19 pa­tients.

This comes two weeks af­ter Mer­ck claimed that their an­tivi­ral pill re­duced the chance that new­ly di­ag­nosed Covid-19 pa­tients would be hos­pi­tal­ized or die by 50%. The phar­ma made the an­nounce­ment af­ter in­ter­im da­ta on 775 pa­tients in their clin­i­cal tri­al showed the an­tivi­ral’s po­ten­tial.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.